Neil K. Taunk, MD, MSCTS

Radiopharmaceutical therapy currently falls somewhere between localized treatment and systemic therapy, according to Mallika Marar, MD, MBA.

Rethinking dose fractions and managing subclinical renal and marrow toxicity represent ongoing challenges associated with the use of radiopharmaceutical therapy.

Experts discussed the rapidly expanding radiopharmaceutical paradigm and how to integrate such technology into real-world oncology practice.